ClinicalTrials.gg
TerminatedNCT01557452Updated Apr 6, 2021Results posted

Open-Label Extension of the Dose Finding Study (DSC/08/2357/36) in Patients With Poly Juvenile Idiopathic Arthritis

An interventional study of Givinostat in Juvenile Idiopathic Arthritis, sponsored by Italfarmaco. Terminated at 1 site in Czechia. Open to participants aged 2 Years to 18 Years. Per ClinicalTrials.gov, last updated 2021-04-06.

Sponsored by Italfarmaco · Not applicable, Interventional, and Treatment

Why this study was terminated
Previous study DSC/08/2357/36 did not show efficacy for Givinostat in JIA. Sponsor decision to stop development of Givinostat in polyarticular course Juvenile Idiopathic Arthritis wasn't related to any tolerability concerns.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1
Allocation
Not applicable
Ages
2 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies in Arthritis, Juvenile with a site in Czechia — 3 open to participants now, 5 under way, 5 of them phase 3. Arthritis, Juvenile · Czechia.

Enrollment
13th of 13
1 · median 101
Started
2011
the only one that year
No phase
Only one
of the 14
Registered
6th of 14
by date
Lead sponsor
2 of 14
Italfarmaco

Among the 14 studies in Arthritis, Juvenile with a site in Czechia, this one is the 13th largest by enrollment of the 13 interventional ones that give a count, is the only one that started in 2011, is the only one with no phase, and was the 6th registered.

Arthritis, Juvenile

366 studies on the registry are indexed under Arthritis, Juvenile; 102 are open to participants now.

Browse Arthritis, Juvenile studies →

Open to participants now

3 of the 14 studies in Arthritis, Juvenile with a site in Czechia are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Czechia have not opened yet or have stopped. Only those recruiting at a site in Czechia →

Who these studies take

Of the 69 Arthritis, Juvenile studies recruiting now, 13 (19%) set no upper age limit and 50 (72%) stop at 75 or younger; 65 take children under 18; 11 take healthy volunteers.

This study: 2 Years to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Arthritis, Juvenile with a site in Czechia, or all of them as a file.
02

Study summary

Primary Objective of the study:

the purpose of this extension study was to determine the safety of Givinostat in a long term treatment of patients who participated in DSC/08/2357/36 study with good results (clinical benefit at least pediACR30 response);

Read the detailed description

Givinostat is expected to exert a clinically relevant therapeutic effect on polyarticular JIA through the inhibition of the production/release of pro-inflammatory cytokines, such as IL-1β, IL-6 and TNFα, which are involved in the pathogenesis of the arthritic process.

03

Conditions studied

  • Juvenile Idiopathic Arthritis

Browse trials for

Keywords

  • JIA
04

Who can participate

Ages eligible
2 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • subjects who had successfully completed the previous Dose Finding Study and were fully compliant to the inclusion/exclusion criteria described in the previous DSC/08/2357/36

Exclusion criteria

Exclusion Criteria:

  • patients with fever related to JIA or other systemic features of JIA during 12 months before entering the study
  • active bacterial or mycotic infection requiring antimicrobial treatment
  • episode of macrophage activation syndrome over the last 6 months
  • baseline prolongation of /QTc interval, use of concomitant medications that prolong the QT/QTc interval or history of additional risk factors for TdP.
  • cardiovascular disease
  • clinically significant illness i.e. any condition that in the opinion of the Investigator places the patient to unacceptable risk for adverse outcome if he/she were to participate in the study
  • psychiatric illness/social situation that would limit compliance with study medication and protocol requirements
  • inherited metabolic diseases
  • presence of
  • pregnancy or lactation
  • positive blood test for
  • active EBV infection, active B and/or C hepatitis
  • count \<100x10(9)/L
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
1 participant (actual)

Study arms

  • Experimental
    Givinostat

    Patient received the dose of 0.75 mg/kg BID from December 28th, 2011 to January 27th, 2014

    Drug: Givinostat

Interventions

  • ready-to-use oral suspension, administered in fed condition and on a outpatient basis, especially intended for paediatric patients

    Also known as: ITF2357

06

What researchers measure

Primary outcomes

  1. Number of Participants With Serious Adverse Events (SAE) and Adverse Events (AE) of Interest

    During the entire study period it was reported only one adverse event considered not drug related by the investigator (Mild flu at week 107 of study treatment). No action was taken and the patient recovered spontaneously

    Time frame: Through end of treatment, up to 108 weeks.

Secondary outcomes

  1. Number of Patients Who Maintained PedACR30 Response

    This is an open-label treatment extension of the 2010-019094-15 study, an antecedent dose-ranging trial of Givinostat ready-to-use oral suspension formulation. Eligible patients were those who had completed the previous study achieving a clinical benefit, i.e. patients achieving at least an ACR Paediatric 30 (PedACR30). PedACR30 is defined as at least a 30% improvement from baseline in any three of the following six variables in juvenile idiopathic arthritis (JIA) patients, with no more than one variable worsening by more than 30%: * physician's global assessment of disease activity; * parent/guardian's or patient's global assessment of overall wellbeing; * functional ability; * number of joints with active arthritis; * number of joints with limited range of motion; * ESR. (ACR stands for American College of Rheumatology)

    Time frame: At weeks 48, 60 and 108

  2. Number of Patients Who Reached PedACR70 Response

    This is an open-label treatment extension of the 2010-019094-15 study, an antecedent dose-ranging trial of Givinostat ready-to-use oral suspension formulation. Eligible patients were those who had completed the previous study achieving a clinical benefit, i.e. patients achieving at least an ACR Paediatric 30 (PedACR30). PedACR70 is defined as at least a 70% improvement from baseline in any three of the following six variables in juvenile idiopathic arthritis (JIA) patients, with no more than one variable worsening by more than 30%: * physician's global assessment of disease activity; * parent/guardian's or patient's global assessment of overall wellbeing; * functional ability; * number of joints with active arthritis; * number of joints with limited range of motion; * ESR. (ACR stands for American College of Rheumatology)

    Time frame: At weeks 48, 60 and 108

07

Results

Posted Apr 6, 2021

Participant flow

Participant flow — Overall Study
MilestoneGivinostat
Started1
Completed1
Not completed0

Outcome measures

PrimaryNumber of Participants With Serious Adverse Events (SAE) and Adverse Events (AE) of Interest

During the entire study period it was reported only one adverse event considered not drug related by the investigator (Mild flu at week 107 of study treatment). No action was taken and the patient recovered spontaneously

Time frame:
Through end of treatment, up to 108 weeks.
Reported as:
Number · participants
Number of Participants With Serious Adverse Events (SAE) and Adverse Events (AE) of Interest
participantsGivinostat
non serious AE1
serious AE0
SecondaryNumber of Patients Who Maintained PedACR30 Response

This is an open-label treatment extension of the 2010-019094-15 study, an antecedent dose-ranging trial of Givinostat ready-to-use oral suspension formulation. Eligible patients were those who had completed the previous study achieving a clinical benefit, i.e. patients achieving at least an ACR Paediatric 30 (PedACR30). PedACR30 is defined as at least a 30% improvement from baseline in any three of the following six variables in juvenile idiopathic arthritis (JIA) patients, with no more than one variable worsening by more than 30%: * physician's global assessment of disease activity; * parent/guardian's or patient's global assessment of overall wellbeing; * functional ability; * number of joints with active arthritis; * number of joints with limited range of motion; * ESR. (ACR stands for American College of Rheumatology)

Time frame:
At weeks 48, 60 and 108
Reported as:
Number · participants
Number of Patients Who Maintained PedACR30 Response
participantsGivinostat
week 481
week 600
week 1081
SecondaryNumber of Patients Who Reached PedACR70 Response

This is an open-label treatment extension of the 2010-019094-15 study, an antecedent dose-ranging trial of Givinostat ready-to-use oral suspension formulation. Eligible patients were those who had completed the previous study achieving a clinical benefit, i.e. patients achieving at least an ACR Paediatric 30 (PedACR30). PedACR70 is defined as at least a 70% improvement from baseline in any three of the following six variables in juvenile idiopathic arthritis (JIA) patients, with no more than one variable worsening by more than 30%: * physician's global assessment of disease activity; * parent/guardian's or patient's global assessment of overall wellbeing; * functional ability; * number of joints with active arthritis; * number of joints with limited range of motion; * ESR. (ACR stands for American College of Rheumatology)

Time frame:
At weeks 48, 60 and 108
Reported as:
Number · participants
Number of Patients Who Reached PedACR70 Response
participantsGivinostat
week 480
week 601
week 1080

Adverse events

Collected over Through end of treatment, up to 108 weeks.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Givinostat0/1 (0%)0/1 (0%)1/1 (100%)
Most frequent other events
Most frequent other events
EventGivinostat
InfluenzaInfections and infestations1/1

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Givinostat
<=18 years1
Between 18 and 65 years0
>=65 years0
Sex: Female, Male
Sex: Female, Male(Participants)Givinostat
Female1
Male0
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Givinostat
Hispanic or Latino0
Not Hispanic or Latino1
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)Givinostat
Czechia1
08

Study locations

1 site
  • 1st Faculty of Medicine and General Faculty Hospital
    Praha, 12109, Czechia
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2011 to primary completion in Jan 2014, 24 months.

Results were first posted in Apr 2021, 7 years 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 14, 2012
First posted
Mar 19, 2012
StartActual
Dec 28, 2011
Primary completionActual
Jan 27, 2014
CompletionActual
Jan 27, 2014
Results first posted
Apr 6, 2021
Last update
Apr 6, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 6, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01557452
Lead sponsor
Italfarmaco
Collaborators
Parexel
Responsible party
Sponsor
First posted
Mar 19, 2012
Start date
Dec 28, 2011
Primary completion
Jan 27, 2014
Completion
Jan 27, 2014
Results posted
Apr 6, 2021
Last update
Apr 6, 2021

Study contacts

Pavla Dolezalova, MD
principal investigator · General Faculty Hospital Department of Pediatrics and Adolescent Medicine, Praha, Czech Republic

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Givinostat

Start the discussion